Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1997 1
1999 1
2002 1
2003 3
2004 1
2005 1
2006 3
2008 1
2009 5
2010 2
2013 2
2014 6
2015 6
2016 10
2017 10
2018 9
2019 12
2020 19
2021 15
2022 17
2023 15
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for busico
Search for Busi O instead (2 results)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Cremolini C, et al. JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. JAMA Oncol. 2019. PMID: 30476968 Free PMC article. Clinical Trial.
Can we define breast cancer HER2 status by liquid biopsy?
Di Cosimo S, De Marco C, Silvestri M, Busico A, Vingiani A, Pruneri G, Cappelletti V. Di Cosimo S, et al. Int Rev Cell Mol Biol. 2023;381:23-56. doi: 10.1016/bs.ircmb.2023.07.003. Epub 2023 Sep 4. Int Rev Cell Mol Biol. 2023. PMID: 37739483 Review.
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
Pusceddu S, Corti F, Prinzi N, Nichetti F, Ljevar S, Busico A, Cascella T, Leporati R, Oldani S, Pircher CC, Coppa J, Resi V, Milione M, Maccauro M, Miceli R, Tamborini E, Perrone F, Spreafico C, Niger M, Morano F, Pietrantonio F, Seregni E, Mariani L, Mazzaferro V, Di Liberti G, Fucà G, de Braud F, Vernieri C. Pusceddu S, et al. J Hematol Oncol. 2023 Dec 14;16(1):119. doi: 10.1186/s13045-023-01510-9. J Hematol Oncol. 2023. PMID: 38098114 Free PMC article. Clinical Trial.
Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors.
Minna E, Devecchi A, Pistore F, Paolini B, Mauro G, Penso DA, Pagliardini S, Busico A, Pruneri G, De Cecco L, Borrello MG, Sensi M, Greco A. Minna E, et al. Front Endocrinol (Lausanne). 2023 Oct 5;14:1267499. doi: 10.3389/fendo.2023.1267499. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37867524 Free PMC article.
Molecular profiling of pediatric and young adult colorectal cancer reveals a distinct genomic landscapes and potential therapeutic avenues.
Busico A, Gasparini P, Rausa E, Cattaneo L, Bozzi F, Silvestri M, Capone I, Conca E, Tamborini E, Perrone F, Vitellaro M, Ricci MT, Casanova M, Chiaravalli S, Bergamaschi L, Massimino M, Milione M, Sozzi G, Pruneri G, Ferrari A, Signoroni S. Busico A, et al. Sci Rep. 2024 Jun 7;14(1):13138. doi: 10.1038/s41598-024-64149-7. Sci Rep. 2024. PMID: 38849509 Free PMC article.
Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
Centonze G, Maisonneuve P, Prinzi N, Pusceddu S, Albarello L, Pisa E, Barberis M, Vanoli A, Spaggiari P, Bossi P, Cattaneo L, Sabella G, Solcia E, La Rosa S, Grillo F, Tagliabue G, Scarpa A, Papotti M, Volante M, Mangogna A, Del Gobbo A, Ferrero S, Rolli L, Roca E, Bercich L, Benvenuti M, Messerini L, Inzani F, Pruneri G, Busico A, Perrone F, Tamborini E, Pellegrinelli A, Kankava K, Berruti A, Pastorino U, Fazio N, Sessa F, Capella C, Rindi G, Milione M. Centonze G, et al. Neuroendocrinology. 2023;113(4):457-469. doi: 10.1159/000528186. Epub 2022 Nov 23. Neuroendocrinology. 2023. PMID: 36417840 Free article.
Follow-up program after intensive care unit discharge.
Busico M, das Neves A, Carini F, Pedace M, Villalba D, Foster C, García Urrutia J, Garbarini M, Jereb S, Sacha V, Estenssoro E. Busico M, et al. Med Intensiva (Engl Ed). 2019 May;43(4):243-254. doi: 10.1016/j.medin.2018.12.005. Epub 2019 Mar 2. Med Intensiva (Engl Ed). 2019. PMID: 30833016 English, Spanish.
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.
Germani MM, Vetere G, Giordano M, Ciracì P, Capone I, Tamborini E, Conca E, Busico A, Pietrantonio F, Piva VM, Boccaccino A, Simionato F, Bortolot M, Manca P, Lonardi S, Conca V, Borelli B, Carullo M, Del Re M, Fontanini G, Rossini D, Cremolini C. Germani MM, et al. Front Oncol. 2024 Feb 9;13:1307545. doi: 10.3389/fonc.2023.1307545. eCollection 2023. Front Oncol. 2024. PMID: 38406172 Free PMC article.
131 results